FDA votes could change access to controversial peptide treatments. Find out which peptides were approved and what happens next.

FDA votes on several controversial peptide treatments could change how patients access these unapproved therapies in the future. The Food and Drug Administration panel backed allowing compounding pharmacies to make six of the seven peptides under review for patients with a valid prescription, even though FDA staff said there is limited evidence about their safety and effectiveness. The recommendation is an important step, but the FDA will make the final decision.

The two-day meeting concluded with advisers supporting access to peptides including BPC-157, TB-500, KPV, Epitalon, and Semax. However, the panel voted against allowing the compounding of emideltide, a peptide marketed as a sleep aid.

A Major Change Despite Safety Concerns

The vote marks a major change from restrictions introduced during the Biden administration, when officials concluded that several peptides lacked enough evidence to justify legal compounding. FDA staff continued to argue that the available scientific data remains too limited to support broader access.

Supporters, however, believe regulated access could be safer than leaving patients to purchase products from the largely unregulated online market, where peptides have become increasingly popular.

"We didn't approve a drug. Nobody put a finished product on a shelf. We took a decision that patients are already making, and we try to keep it inside a system that has rules and regulations," said Haleem Mohammed, a voting member and chief medical officer at Gameday Health.

Why Are Peptides Suddenly So Popular?

Peptides are short chains of amino acids that naturally occur in the body and help regulate many biological functions. Some FDA-approved peptides are already used to treat medical conditions such as diabetes. Recently, unapproved peptides have gained popularity through social media and wellness influencers. They are often promoted as solutions for faster muscle recovery, anti-aging, skin improvement, gut health, and even "biohacking" or "looksmaxxing." Many of these claims have not been confirmed through large human clinical trials.

One of the best-known examples is BPC-157, which is marketed online for tissue repair and inflammation. Although animal studies have shown some promise, experts say there is still insufficient evidence proving it is safe or effective for people. The World Anti-Doping Agency also bans BPC-157 in competitive sports.

Could This Decision Change the Market?

The advisory panel's recommendations are seen as a win for Health Secretary Robert F. Kennedy Jr., who has publicly supported peptides and argued that patients are already accessing them through unregulated channels. The decision could also create a major opportunity for telehealth companies and compounding pharmacies. Industry analysts estimate that a regulated peptide market could eventually grow into a $2 billion to $3 billion business if the FDA approves broader access.

Still, not everyone is convinced. Critics have questioned whether some advisory panel members may have conflicts of interest because several work for businesses that sell peptide treatments. Federal officials responded that all members completed the standard ethics review and vetting process required for FDA advisory committees.

What Happens Next?

The advisory committee's vote does not automatically change the rules. The FDA is not required to follow the recommendations, although it often considers expert panel advice when making final decisions.

If the agency approves expanded access, patients may be able to obtain certain compounded peptides through prescriptions instead of relying on unregulated online sellers. As Business Fortune observes, health experts continue to call for stronger clinical research to better understand the long-term benefits and risks of these treatments.

 

FAQs

What did the FDA advisory panel vote on?

The panel recommended allowing compounding pharmacies to produce six unapproved peptides for patients with prescriptions while rejecting one peptide, emideltide.

Are these peptides officially approved by the FDA?

No. The peptides discussed remain unapproved. The panel's recommendations are advisory, and the FDA will make the final decision.

What are peptides?

Peptides are short chains of amino acids that naturally occur in the body and help regulate important biological processes. Some are already used in approved medicines, while others remain experimental.

Why are experts concerned about these peptides?

Many of the popular peptides have not been thoroughly tested in large human clinical trials, leaving questions about their safety, effectiveness, and long-term side effects.

What could happen if the FDA accepts the recommendations?

Compounding pharmacies could legally produce certain peptides for patients with prescriptions, potentially reducing reliance on unregulated online products while expanding access under medical supervision.